NO945021L - Compositions for Inhibition of Protein Hormone Formation and Use thereof - Google Patents

Compositions for Inhibition of Protein Hormone Formation and Use thereof

Info

Publication number
NO945021L
NO945021L NO945021A NO945021A NO945021L NO 945021 L NO945021 L NO 945021L NO 945021 A NO945021 A NO 945021A NO 945021 A NO945021 A NO 945021A NO 945021 L NO945021 L NO 945021L
Authority
NO
Norway
Prior art keywords
inhibition
compositions
protein hormone
hormone formation
treatment
Prior art date
Application number
NO945021A
Other languages
Norwegian (no)
Other versions
NO945021D0 (en
Inventor
Michael Kriegler
Carl Perez
Robert Forgan Halenbeck
David A Jewell
Kirston E Koths
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/006120 external-priority patent/WO1994000555A2/en
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Publication of NO945021D0 publication Critical patent/NO945021D0/en
Publication of NO945021L publication Critical patent/NO945021L/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Forbindelser med proteolytisk inhibitorisk aktivitet som er nyttige for behandling av sykdommer, spesielt for behandling av sepsis, AIDS eller autoimmune sykdommer som er et resultat av en reduksjon i det sirkulerende nivået av modne proteinhormoner avledet fra den proteolytisk spaltningen av prohormonforløpere så som 26 kD TNF, og fremgangsmåter for identifisering av forbindelser som har ønsket inhibitorisk aktivitet er tilveiebragt.Compounds with proteolytic inhibitory activity useful for the treatment of diseases, in particular for the treatment of sepsis, AIDS or autoimmune diseases which result from a reduction in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kD TNF, and methods for identifying compounds that have desired inhibitory activity are provided.

NO945021A 1992-06-25 1994-12-23 Compositions for Inhibition of Protein Hormone Formation and Use thereof NO945021L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90554692A 1992-06-25 1992-06-25
PCT/US1993/006120 WO1994000555A2 (en) 1992-06-25 1993-06-25 Compositions for the inhibition of protein hormone formation and uses thereof

Publications (2)

Publication Number Publication Date
NO945021D0 NO945021D0 (en) 1994-12-23
NO945021L true NO945021L (en) 1995-02-17

Family

ID=26786840

Family Applications (1)

Application Number Title Priority Date Filing Date
NO945021A NO945021L (en) 1992-06-25 1994-12-23 Compositions for Inhibition of Protein Hormone Formation and Use thereof

Country Status (1)

Country Link
NO (1) NO945021L (en)

Also Published As

Publication number Publication date
NO945021D0 (en) 1994-12-23

Similar Documents

Publication Publication Date Title
NO20092860L (en) 2, 6 dioxopiperidine and pharmaceutical compositions containing them
ES2146552A1 (en) Tgf g beta1 inhibitor peptides
ATE293883T1 (en) USE OF ANTIOXIDANTS TO TREAT CHOLESTATIC LIVER DISEASE
DK0697019T3 (en) Risperidone pamoater
DE69326776D1 (en) USE OF N-ARYLMETHYLEN ETHYLENDIAMINTRIACETATE, N-ARYLMETHYLEN IMINODIACETAT OR N, N'-DIARYLMETHYLEN ETHYLENDIAMINDIACETAT AGAINST OXIDATIVE STRESS
ATE262895T1 (en) USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF DISEASES CAUSED BY AMYLOIDOSIS
ATE192045T1 (en) USE OF SUBSTITUTED ADENINE DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLERosis
KR950700333A (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR ITS PRODUCTION FROM HUMAN PERIPHERAL BLOOD LEUKOCYTES
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DK0844874T3 (en) Methods and compositions suitable for inhibiting alpha v beta 5-mediated angiogenesis
DE59611411D1 (en) USE OF ALPHA 1L AGONISTS FOR THE TREATMENT OF HARNINE CONTINENCE
ATE474597T1 (en) INHIBITION OF THE MIGRATION INHIBITION FACTOR IN THE TREATMENT OF DISEASES IN WHICH CYTOKINE-MEDIATED TOXICITY PLAYS A ROLE
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
DE69109583D1 (en) Procedure for the treatment of inflammatory bowel diseases.
ATE170868T1 (en) PEPTIDE PHOSPHINYLOXYMETHYL KETONES AS INHIBITORS OF INTERLEUKIN-1 BETA-CONVERTING ENZYMES
ATE147981T1 (en) ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS
WO1994000555A3 (en) Compositions for the inhibition of protein hormone formation and uses thereof
DE69230041D1 (en) MURAMYL COMPOUNDS FOR TREATING SEPTIC SHOCK
MX9701776A (en) Use of insulin-like growth factors (i) and (ii) for inhibition of inflammatory response.
ES2135398T3 (en) COMPOUND AND COMPOSITIONS OF INHIBITION OF BONE RESORPTION.
ATE297739T1 (en) ENDOTHELIN ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE
NO945021L (en) Compositions for Inhibition of Protein Hormone Formation and Use thereof
ATE408415T1 (en) INHIBITORS FOR NEW VASCULAR FORMATION
DE69814089D1 (en) USE OF A DRAFLAZINE ANALOGUE FOR TREATMENT
DE69800966T2 (en) SPERM THINNER CONTAINING NATIVE PHOSPHOCASEINATE OR BETA LACTOGLOBULIN, METHOD FOR THE PRODUCTION THEREOF AND ITS USE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application